Ramanan Vijay
Department of Clinical Haematology and Bone Marrow Transplant, Ruby Hall Clinic, Pune, Maharashtra, India.
Asian J Transfus Sci. 2021 Jul-Dec;15(2):250-252. doi: 10.4103/ajts.ajts_109_20. Epub 2021 Nov 1.
Beta-thalassemia major is characterized by a genetic deficiency in synthesis of beta-globin chains, resulting in reduced levels of functional hemoglobin. It is characterized by anemia, hepatosplenomegaly, and iron overload due to repeated blood transfusion. Hematopoietic stem cell transplantation is currently the only known curative treatment. We present a case of a 10-year-old girl with beta-thalassemia major who was successfully cured with allogeneic booster umbilical cord blood (UCB) transplantation with outcome data after 3 years of transplantation, in India. Postdiagnosis, she was on regular once-a-month blood transfusion until the age of 10 years, with no improvement. No serious adverse events occurred in the patient post-UCB transplantation. Chronic graft versus host disease was limited and was managed by medicines. Signs of primary graft rejection were also not seen.
重型β地中海贫血的特征是β珠蛋白链合成存在基因缺陷,导致功能性血红蛋白水平降低。其特点为贫血、肝脾肿大以及因反复输血导致的铁过载。造血干细胞移植是目前已知的唯一治愈性疗法。我们报告了一例10岁的重型β地中海贫血女孩,在印度接受了异基因强化脐带血移植并获得成功治愈,同时给出了移植3年后的预后数据。确诊后,她每月定期输血直至10岁,病情并无改善。脐带血移植后患者未发生严重不良事件。慢性移植物抗宿主病症状较轻,通过药物进行控制。也未观察到原发性移植物排斥的迹象。